Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

PNH-driven hepatic vein thrombosis: A case of budd-chiari syndrome in disguise“

Sai Prasad, Shaily Agrawal, Advaitha Reddy, Vidhi Parmar, Riti Aggarwal

Blood (2025) 146 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2025-6740

Published: 2025

Journal Articles

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood blood.2024027009.

https://doi.org/10.1182/blood.2024027009

Published: 2025

Includes: Supplemental data

Journal Articles

Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease

Sai Prasad Ramachandran, Jingchen Liang, Daniel Prior, Priyanshi Maurya, Yanhong Deng, Lakshmanan Krishnamurti

Blood (2024) 144 (Supplement 1): 2304.

https://doi.org/10.1182/blood-2024-212065

Published: 2024

Journal Articles

Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Priyanshi Maurya, Jingchen Liang, Daniel Prior, Sai Prasad Ramachandran, Yanhong Deng, Lakshmanan Krishnamurti

Blood (2024) 144 (Supplement 1): 2302.

https://doi.org/10.1182/blood-2024-211601

Published: 2024

Journal Articles

Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Priyanshi Maurya, Jingchen Liang, Daniel Prior, Sai Prasad Ramachandran, Yanhong Deng, Lakshmanan Krishnamurti

Blood (2024) 144 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2024-211409

Published: 2024

Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Blood (2023) 142 (Supplement 1): 326.

https://doi.org/10.1182/blood-2023-180143

Published: 2023

Journal Articles

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver, Sanam Loghavi, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Sherry A. Pierce, Keyur P. Patel, Hussein A Abbas, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 11788–11790.

https://doi.org/10.1182/blood-2022-166655

Published: 2022

Journal Articles

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 534–536.

https://doi.org/10.1182/blood-2022-164922

Published: 2022

Journal Articles

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

Sai Prasad Desikan, Hagop Kantarjian, Elias Jabbour, Kelly S. Chien, Guillermo Montalban-Bravo, Yesid Alvarado, Gautam Borthakur, Ghayas C. Issa, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Danielle Hammond, Abhishek Maiti, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3301–3303.

https://doi.org/10.1182/blood-2022-169824

Published: 2022

Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda

Blood (2022) 140 (Supplement 1): 9876–9878.

https://doi.org/10.1182/blood-2022-167284

Published: 2022

Journal Articles

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 2298.

https://doi.org/10.1182/blood-2021-153795

Published: 2021

Journal Articles

A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Sai Prasad Desikan, Hagop Kantarjian, Courtney D. DiNardo, Gautam Borthakur, Naval Daver, Naveen Pemmaraju, Yesid Alvarado, Jan A. Burger, Debra Bull Linderman, Sherry A. Pierce, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2021) 138 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2021-151605

Published: 2021

Journal Articles

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

Sai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, Marina Konopleva, Sanam Loghavi, Gautam Borthakur, Elias J. Jabbour, Naval Daver, Nitin Jain, Kelly S. Chien, Abhishek Maiti, Guillermo Montalban-Bravo, Tapan M. Kadia, Monica Kwari, Hagop Kantarjian, Nicholas J. Short

Blood (2021) 138 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2021-151707

Published: 2021

Journal Articles

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Sai Prasad Prasad Desikan, Guillermo Montalban-Bravo, Maro Ohanian, Naval Daver, Musa Yilmaz, Marina Konopleva, Tapan M. Kadia, Sangeetha Venugopal, Heather Schneider, Kelly S. Chien, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2021-153170

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

PNH-driven hepatic vein thrombosis: A case of budd-chiari syndrome in disguise“

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease

Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only